Daniel W. Coyne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel W. Coyne has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Claudy Mullon
Fresenius Medical Care Renal Therapies Group, Waltham, MA
7 shared publicationsRobert J. Kossmann
Fresenius Medical Care Renal Therapies Group, Waltham, MA
7 shared publications- Linda H. Ficociello
Renal Research Institute, New York, New York
6 shared publications - Kamyar Kalantar-Zadeh
Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, California
4 shared publications Nicolaos V. Athienites
Renal Medical Care PC
4 shared publicationsStuart M. Sprague
Division of Nephrology and Hypertension, NorthShore University Health System, University of Chicago Pritzker School of Medicine, Evanston, USA
4 shared publications
Latest Publications
- 9 August 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (9) , 1111-1112
Iron Repletion for Patients with Heart Failure and Kidney Dysfunction
- 9 August 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (9) , 1111-1112
Iron Repletion for Patients with Heart Failure and Kidney Dysfunction
- 1 September 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (9) , 1325-1336
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Background and objectives: Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior erythropoiesis-stimulating agent (ESA). Design, setting, participants, & measurements: Patients on hemodialysis with a baseline hemoglobin of 8–11.5 g/dl receiving an ESA were randomized 2:1 to daprodustat three times weekly (n=270) or conventional epoetin (n=137) for 52 weeks. Dosing algorithms aimed to maintain hemoglobin between 10 and 11 g/dl. The primary end point was mean change in hemoglobin from baseline to the average during the evaluation period (weeks 28–52). The principal secondary end point was average monthly intravenous iron dose. Other secondary end points included BP and hemoglobin variability. Results: Daprodustat three times weekly was noninferior to epoetin for mean change in hemoglobin (model-adjusted mean treatment difference [daprodustat-epoetin], −0.05; 95% confidence interval, −0.21 to 0.10). During the evaluation period, mean (SD) hemoglobin values were 10.45 (0.55) and 10.51 (0.85) g/dl for daprodustat and epoetin groups, respectively. Responders (defined as mean hemoglobin during the evaluation period in the analysis range of 10 to 11.5 g/dl) were 80% in the daprodustat group versus 64% in the epoetin group. Proportionately fewer participants in the daprodustat group versus the epoetin group had hemoglobin values either below 10 g/dl or above 11.5 g/dl during the evaluation period. Mean monthly intravenous iron use was not significantly lower with daprodustat versus epoetin. The effect on BP was similar between groups. The percentage of treatment-emergent adverse events was similar between daprodustat (75%) and epoetin (79%). Conclusions: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated. Clinical Trial registry name and registration number: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat–Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033
- 1 September 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (9) , 1325-1336
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Background and objectives: Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior erythropoiesis-stimulating agent (ESA). Design, setting, participants, & measurements: Patients on hemodialysis with a baseline hemoglobin of 8–11.5 g/dl receiving an ESA were randomized 2:1 to daprodustat three times weekly (n=270) or conventional epoetin (n=137) for 52 weeks. Dosing algorithms aimed to maintain hemoglobin between 10 and 11 g/dl. The primary end point was mean change in hemoglobin from baseline to the average during the evaluation period (weeks 28–52). The principal secondary end point was average monthly intravenous iron dose. Other secondary end points included BP and hemoglobin variability. Results: Daprodustat three times weekly was noninferior to epoetin for mean change in hemoglobin (model-adjusted mean treatment difference [daprodustat-epoetin], −0.05; 95% confidence interval, −0.21 to 0.10). During the evaluation period, mean (SD) hemoglobin values were 10.45 (0.55) and 10.51 (0.85) g/dl for daprodustat and epoetin groups, respectively. Responders (defined as mean hemoglobin during the evaluation period in the analysis range of 10 to 11.5 g/dl) were 80% in the daprodustat group versus 64% in the epoetin group. Proportionately fewer participants in the daprodustat group versus the epoetin group had hemoglobin values either below 10 g/dl or above 11.5 g/dl during the evaluation period. Mean monthly intravenous iron use was not significantly lower with daprodustat versus epoetin. The effect on BP was similar between groups. The percentage of treatment-emergent adverse events was similar between daprodustat (75%) and epoetin (79%). Conclusions: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated. Clinical Trial registry name and registration number: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat–Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033
- Open Access
- 1 April 2022
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 15, 139-149
Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
Purpose: In prior analyses of real-world cohorts of hemodialysis patients switched from one phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated with improvements in serum phosphorus (sP) and reductions in daily PB pill burden. To characterize how SO initiation patterns have changed over time, we examined the long-term effectiveness of SO in a contemporary (2018– 2019) cohort. Patients and Methods: Adult Fresenius Kidney Care hemodialysis patients first prescribed SO monotherapy as part of routine care between May 2018 and May 2019 (N = 1792) were followed for 1 year. All patients received a non-SO PB during a 91-day baseline period before SO prescription. Mean PB pills/day and laboratory parameters were compared before and during SO treatment. Results were divided into consecutive 91-day intervals (Q1–Q4) and analyzed using linear mixed-effects regression and Cochran’s Q test. These results were contrasted with findings from a historical (2014– 2015) cohort (N = 530). Results: The proportion of patients achieving sP ≤ 5.5 mg/dl increased after switching to SO (from 27.0% at baseline to 37.8%, 45.1%, 44.7%, and 44.0% at Q1, Q2, Q3, and Q4, respectively; P < 0.0001 for all). The mean daily PB pill burden decreased from a baseline of 7.7 to 4.4, 4.6, 4.8, and 4.9, respectively, across quarters (P < 0.0001 for all). Patients in the contemporary cohort had improved sP control (27.0% achieving sP ≤ 5.5 mg/dl vs 17.7%) and lower daily PB pill burden (mean 7.7 vs 8.5 pills/day) at baseline than those in the historical cohort. Overall use of active vitamin D was similar between cohorts, although higher use of oral active vitamin D (63.9% vs 15.7%) and lower use of IV active vitamin D lower (23.4% vs 74.2%) was observed in the contemporary cohort. Conclusion: Despite evolving treatment patterns, switching to SO resulted in improved sP control with fewer pills per day in this contemporary hemodialysis cohort.
- 1 April 2022
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 15, 139-149
Open AccessSerum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
Purpose: In prior analyses of real-world cohorts of hemodialysis patients switched from one phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated with improvements in serum phosphorus (sP) and reductions in daily PB pill burden. To characterize how SO initiation patterns have changed over time, we examined the long-term effectiveness of SO in a contemporary (2018– 2019) cohort. Patients and Methods: Adult Fresenius Kidney Care hemodialysis patients first prescribed SO monotherapy as part of routine care between May 2018 and May 2019 (N = 1792) were followed for 1 year. All patients received a non-SO PB during a 91-day baseline period before SO prescription. Mean PB pills/day and laboratory parameters were compared before and during SO treatment. Results were divided into consecutive 91-day intervals (Q1–Q4) and analyzed using linear mixed-effects regression and Cochran’s Q test. These results were contrasted with findings from a historical (2014– 2015) cohort (N = 530). Results: The proportion of patients achieving sP ≤ 5.5 mg/dl increased after switching to SO (from 27.0% at baseline to 37.8%, 45.1%, 44.7%, and 44.0% at Q1, Q2, Q3, and Q4, respectively; P < 0.0001 for all). The mean daily PB pill burden decreased from a baseline of 7.7 to 4.4, 4.6, 4.8, and 4.9, respectively, across quarters (P < 0.0001 for all). Patients in the contemporary cohort had improved sP control (27.0% achieving sP ≤ 5.5 mg/dl vs 17.7%) and lower daily PB pill burden (mean 7.7 vs 8.5 pills/day) at baseline than those in the historical cohort. Overall use of active vitamin D was similar between cohorts, although higher use of oral active vitamin D (63.9% vs 15.7%) and lower use of IV active vitamin D lower (23.4% vs 74.2%) was observed in the contemporary cohort. Conclusion: Despite evolving treatment patterns, switching to SO resulted in improved sP control with fewer pills per day in this contemporary hemodialysis cohort.
- 24 February 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (2) , 208-210
Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO
This is an Early Access article. Please select the PDF button, above, to view it. Be sure to also read the CON: 10.34067/KID.0007152020 and the COMMENTARY 10.34067/KID.0004892021
- 24 February 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (2) , 208-210
Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO
This is an Early Access article. Please select the PDF button, above, to view it. Be sure to also read the CON: 10.34067/KID.0007152020 and the COMMENTARY 10.34067/KID.0004892021
- Open Access
- 9 February 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (3) , 875-888
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease. Most dialysis-dependent patients need oral phosphate binder therapy to control serum phosphorus concentrations. Most phosphate binders have a high daily pill burden, which may reduce treatment adherence and impair phosphorus control. Sucroferric oxyhydroxide is a potent iron-based phosphate binder approved for use in dialysis-dependent patients in 2013. A randomized controlled trial of sucroferric oxyhydroxide demonstrated its efficacy for reduction of serum phosphorus with a lower pill burden than sevelamer carbonate. Clinical trials carefully select patients, monitor adherence, and routinely titrate medications to a protocol-defined goal. Consequently, trials may not reflect real-world use of medications. Since its approval, we and others have performed retrospective and prospective analyses of sucroferric oxyhydroxide in real-world clinical practice in > 6400 hemodialysis and approximately 500 peritoneal dialysis patients in the USA and Europe. Consistent with the clinical trial data, real-world observational studies have demonstrated that sucroferric oxyhydroxide can effectively reduce serum phosphorus with a lower daily pill burden than most other phosphate binders. These studies have also shown sucroferric oxyhydroxide provides effective serum phosphorus control in different treatment settings, including as monotherapy in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with other phosphate binders. These observational studies indicate a favorable safety and tolerability profile, and minimal, if any, systemic iron absorption. This article reviews the key results from these observational studies of sucroferric oxyhydroxide and evaluates its role in the management of hyperphosphatemia in clinical practice.
- 9 February 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (3) , 875-888
Open AccessSucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease. Most dialysis-dependent patients need oral phosphate binder therapy to control serum phosphorus concentrations. Most phosphate binders have a high daily pill burden, which may reduce treatment adherence and impair phosphorus control. Sucroferric oxyhydroxide is a potent iron-based phosphate binder approved for use in dialysis-dependent patients in 2013. A randomized controlled trial of sucroferric oxyhydroxide demonstrated its efficacy for reduction of serum phosphorus with a lower pill burden than sevelamer carbonate. Clinical trials carefully select patients, monitor adherence, and routinely titrate medications to a protocol-defined goal. Consequently, trials may not reflect real-world use of medications. Since its approval, we and others have performed retrospective and prospective analyses of sucroferric oxyhydroxide in real-world clinical practice in > 6400 hemodialysis and approximately 500 peritoneal dialysis patients in the USA and Europe. Consistent with the clinical trial data, real-world observational studies have demonstrated that sucroferric oxyhydroxide can effectively reduce serum phosphorus with a lower daily pill burden than most other phosphate binders. These studies have also shown sucroferric oxyhydroxide provides effective serum phosphorus control in different treatment settings, including as monotherapy in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with other phosphate binders. These observational studies indicate a favorable safety and tolerability profile, and minimal, if any, systemic iron absorption. This article reviews the key results from these observational studies of sucroferric oxyhydroxide and evaluates its role in the management of hyperphosphatemia in clinical practice.
- 16 September 2021
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 52 (10-11) , 894-898
HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety
Treatment options for the anemia of chronic kidney disease (CKD) continue to expand. Several hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are undergoing clinical testing and seeking regulatory approval. Erythropoiesis-stimulating agents (ESAs) have been the cornerstone of anemia therapy since 1989, when first-in-class recombinant human erythropoietin was approved. The rise in hemoglobin (Hb) with ESAs demanded greater need for iron and paradoxically greater iron losses due to the higher Hb concentration. This exacerbated iron deficiency led to markedly increased use of intravenous (IV) iron. ESAs, especially at larger dosages aimed to target higher target Hb levels, increase the risk of cardiovascular and thrombotic events, cancer, and death. Prescribed IV iron therapy, while apparently safer, has limited long-term safety evidence and fills iron stores well beyond the normal range, which in part overcomes hepcidin-mediated iron blockade.
- 16 September 2021
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 52 (10-11) , 894-898
HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety
Treatment options for the anemia of chronic kidney disease (CKD) continue to expand. Several hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are undergoing clinical testing and seeking regulatory approval. Erythropoiesis-stimulating agents (ESAs) have been the cornerstone of anemia therapy since 1989, when first-in-class recombinant human erythropoietin was approved. The rise in hemoglobin (Hb) with ESAs demanded greater need for iron and paradoxically greater iron losses due to the higher Hb concentration. This exacerbated iron deficiency led to markedly increased use of intravenous (IV) iron. ESAs, especially at larger dosages aimed to target higher target Hb levels, increase the risk of cardiovascular and thrombotic events, cancer, and death. Prescribed IV iron therapy, while apparently safer, has limited long-term safety evidence and fills iron stores well beyond the normal range, which in part overcomes hepcidin-mediated iron blockade.
- 3 December 2020
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 32 (1) , 6-8
Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?
- 3 December 2020
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 32 (1) , 6-8
Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?
- Open Access
- 1 September 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (5) , 589-599.e1
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
- 1 September 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (5) , 589-599.e1
Open AccessClinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
- Open Access
- 1 July 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (4) , 385-387
Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD
- 1 July 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (4) , 385-387
Open AccessTesting Vitamin D Analogues for Vascular Calcification in Patients With CKD
- Open Access
- 1 May 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (3) , 307-316
Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
- 1 May 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (3) , 307-316
Open AccessSucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study